IBDEI0JF ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9027,2)
 ;;=^5006368
 ;;^UTILITY(U,$J,358.3,9028,0)
 ;;=H54.8^^41^472^7
 ;;^UTILITY(U,$J,358.3,9028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9028,1,3,0)
 ;;=3^Legal Blindness,as Defined in USA
 ;;^UTILITY(U,$J,358.3,9028,1,4,0)
 ;;=4^H54.8
 ;;^UTILITY(U,$J,358.3,9028,2)
 ;;=^5006369
 ;;^UTILITY(U,$J,358.3,9029,0)
 ;;=H54.10^^41^472^4
 ;;^UTILITY(U,$J,358.3,9029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9029,1,3,0)
 ;;=3^Blindness-One Eye/Low Vision-Other Eye,Unspec Eyes
 ;;^UTILITY(U,$J,358.3,9029,1,4,0)
 ;;=4^H54.10
 ;;^UTILITY(U,$J,358.3,9029,2)
 ;;=^5006358
 ;;^UTILITY(U,$J,358.3,9030,0)
 ;;=E11.9^^41^473^26
 ;;^UTILITY(U,$J,358.3,9030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9030,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,9030,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,9030,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,9031,0)
 ;;=E11.39^^41^473^15
 ;;^UTILITY(U,$J,358.3,9031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9031,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complications
 ;;^UTILITY(U,$J,358.3,9031,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,9031,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,9032,0)
 ;;=E11.36^^41^473^14
 ;;^UTILITY(U,$J,358.3,9032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9032,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Cataract
 ;;^UTILITY(U,$J,358.3,9032,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,9032,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,9033,0)
 ;;=E11.359^^41^473^20
 ;;^UTILITY(U,$J,358.3,9033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9033,1,3,0)
 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,9033,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,9033,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,9034,0)
 ;;=E11.351^^41^473^21
 ;;^UTILITY(U,$J,358.3,9034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9034,1,3,0)
 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,9034,1,4,0)
 ;;=4^E11.351
 ;;^UTILITY(U,$J,358.3,9034,2)
 ;;=^5002640
 ;;^UTILITY(U,$J,358.3,9035,0)
 ;;=E11.349^^41^473^22
 ;;^UTILITY(U,$J,358.3,9035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9035,1,3,0)
 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,9035,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,9035,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,9036,0)
 ;;=E11.341^^41^473^23
 ;;^UTILITY(U,$J,358.3,9036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9036,1,3,0)
 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,9036,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,9036,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,9037,0)
 ;;=E11.339^^41^473^18
 ;;^UTILITY(U,$J,358.3,9037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9037,1,3,0)
 ;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,9037,1,4,0)
 ;;=4^E11.339
 ;;^UTILITY(U,$J,358.3,9037,2)
 ;;=^5002637
 ;;^UTILITY(U,$J,358.3,9038,0)
 ;;=E11.331^^41^473^19
 ;;^UTILITY(U,$J,358.3,9038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9038,1,3,0)
 ;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,9038,1,4,0)
 ;;=4^E11.331
 ;;^UTILITY(U,$J,358.3,9038,2)
 ;;=^5002636
 ;;^UTILITY(U,$J,358.3,9039,0)
 ;;=E11.329^^41^473^16
 ;;^UTILITY(U,$J,358.3,9039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9039,1,3,0)
 ;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,9039,1,4,0)
 ;;=4^E11.329
 ;;^UTILITY(U,$J,358.3,9039,2)
 ;;=^5002635
 ;;^UTILITY(U,$J,358.3,9040,0)
 ;;=E11.321^^41^473^17
